These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 10100104)

  • 21. Double-blind comparison of eprosartan and enalapril on cough and blood pressure in unselected hypertensive patients. Eprosartan Study Group.
    Elliott WJ
    J Hum Hypertens; 1999 Jun; 13(6):413-7. PubMed ID: 10408592
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of eprosartan and enalapril in the treatment of black hypertensive patients: subgroup analysis of a 26-week, double-blind, multicentre study. Eprosartan Multinational Study Group.
    Levine B
    Curr Med Res Opin; 1999; 15(1):25-32. PubMed ID: 10216808
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Candesartan cilexetil: comparison of once-daily versus twice-daily administration for systemic hypertension. Candesartan Cilexetil Study Investigators.
    Zuschke CA; Keys I; Munger MA; Carr AA; Marinides GN; Flanagan TL; Cushing DJ; Hayes JL; Michelson EL
    Clin Ther; 1999 Mar; 21(3):464-74. PubMed ID: 10321416
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Quality of life and cough on antihypertensive treatment: a randomised trial of eprosartan, enalapril and placebo.
    Rake EC; Breeze E; Fletcher AE
    J Hum Hypertens; 2001 Dec; 15(12):863-7. PubMed ID: 11773989
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A twelve-week, multicenter, randomized, double-blind, parallel-group, noninferiority trial of the antihypertensive efficacy and tolerability of imidapril and candesartan in adult patients with mild to moderate essential hypertension: the Iberian Multicenter Imidapril Study on Hypertension (IMISH).
    Palma Gámiz JL; Pêgo M; Contreras EM; Anglada MP; Martínez JO; Esquerra EA; Sagastagoitia Gorostiza JD;
    Clin Ther; 2006 Dec; 28(12):2040-51. PubMed ID: 17296460
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of hypertension therapy based on eprosartan on systolic arterial blood pressure and cognitive function: primary results of the Observational Study on Cognitive function And Systolic Blood Pressure Reduction open-label study.
    Hanon O; Berrou JP; Negre-Pages L; Goch JH; Nádházi Z; Petrella R; Sedefdjian A; Sévenier F; Shlyakhto EV; Pathak A
    J Hypertens; 2008 Aug; 26(8):1642-50. PubMed ID: 18622244
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and tolerability of nebivolol monotherapy by baseline systolic blood pressure: a retrospective analysis of pooled data from two multicenter, 12-week, randomized, double-blind, placebo-controlled, parallel-group, dose-ranging studies in patients with mild to moderate essential hypertension.
    Germino FW
    Clin Ther; 2009 Sep; 31(9):1946-56. PubMed ID: 19843484
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Placebo-controlled comparison of the efficacy and tolerability of once-daily moxonidine and enalapril in mild-to-moderate essential hypertension.
    Küppers HE; Jäger BA; Luszick JH; Gräve MA; Hughes PR; Kaan EC
    J Hypertens; 1997 Jan; 15(1):93-7. PubMed ID: 9050976
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Eprosartan-based hypertension therapy, systolic arterial blood pressure and cognitive function: analysis of Middle East data from the OSCAR study.
    Radaideh GA; Choueiry P; Ismail A; Eid E; Berrou JP; Sedefdjian A; Sévenier F; Pathak A
    Vasc Health Risk Manag; 2011; 7():491-5. PubMed ID: 21915165
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antihypertensive efficacy and safety of olmesartan and ramipril in elderly patients with mild to moderate systolic and diastolic essential hypertension.
    Mallion JM; Omboni S; Barton J; Van Mieghem W; Narkiewicz K; Panzer PK; Puig JG; Stefanadis C; Zweiker R;
    Blood Press Suppl; 2011 Apr; 1():3-11. PubMed ID: 21091270
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety and tolerability of eprosartan in combination with hydrochlorothiazide.
    Böhm M; Sachse A
    Drug Saf; 2002; 25(8):599-611. PubMed ID: 12113644
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of eprosartan on cytoplasmic free calcium mobilization, platelet activation, and microparticle formation in hypertension.
    Labiós M; Martínez M; Gabriel F; Guiral V; Munoz A; Aznar J
    Am J Hypertens; 2004 Sep; 17(9):757-63. PubMed ID: 15363816
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical efficacy of eprosartan.
    Weber M
    Pharmacotherapy; 1999 Apr; 19(4 Pt 2):95S-101S. PubMed ID: 10213528
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparative antihypertensive effects of losartan 50 mg and losartan 50 mg titrated to 100 mg in patients with essential hypertension.
    Ikeda LS; Harm SC; Arcuri KE; Goldberg AI; Sweet CS
    Blood Press; 1997 Jan; 6(1):35-43. PubMed ID: 9116924
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A dose-response study to assess the renal hemodynamic, vascular, and hormonal effects of eprosartan, an angiotensin II AT1-receptor antagonist, in sodium-replete healthy men.
    Ilson BE; Boike SC; Martin DE; Freed MI; Zariffa N; Jorkasky DK
    Clin Pharmacol Ther; 1998 Apr; 63(4):471-81. PubMed ID: 9585802
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety and efficacy of eprosartan, a new angiotensin II receptor blocker.
    Shusterman NH
    Am Heart J; 1999 Sep; 138(3 Pt 2):238-45. PubMed ID: 10467219
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of enalapril and eprosartan on the renal vascular nitric oxide system in human essential hypertension.
    Delles C; Jacobi J; John S; Fleischmann I; Schmieder RE
    Kidney Int; 2002 Apr; 61(4):1462-8. PubMed ID: 11918753
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Eprosartan, an angiotensin II receptor antagonist, does not affect the pharmacodynamics of glyburide in patients with type II diabetes mellitus.
    Martin DE; DeCherney GS; Ilson BE; Jones BA; Boike SC; Freed MI; Jorkasky DK
    J Clin Pharmacol; 1997 Feb; 37(2):155-9. PubMed ID: 9055142
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Losartan and low-dose hydrochlorothiazide in patients with essential hypertension. A double-blind, placebo-controlled trial of concomitant administration compared with individual components.
    MacKay JH; Arcuri KE; Goldberg AI; Snapinn SM; Sweet CS
    Arch Intern Med; 1996 Feb; 156(3):278-85. PubMed ID: 8572837
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and tolerability of once-daily oral fimasartan 20 to 240 mg/d in Korean Patients with hypertension: findings from Two Phase II, randomized, double-blind, placebo-controlled studies.
    Lee H; Yang HM; Lee HY; Kim JJ; Choi DJ; Seung KB; Jeon ES; Ha JW; Rim SJ; Park JB; Shin JH; Oh BH
    Clin Ther; 2012 Jun; 34(6):1273-89. PubMed ID: 22608107
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.